Quinoclamine, a naphthoquinone derivative, is a NF-κB inhibitor. Quinoclamine exhibits anti-cancer activity.
性状
Solid
IC50 & Target[1][2]
NF-κB
体外研究(In Vitro)
Quinoclamine causes differentiation of U-937 cells into macrophage-like cells.Quinoclamine inhibits NF-κB activities in HepG2 cells, with an IC50 of 1.7 μM.Quinoclamine (1-4 μM; 30 minutes ) suppresses endogenous NF-κB activity in HepG2 cells through the inhibition of IκB-α phosphorylation and p65 translocation.Quinoclamine inhibits induced NF-κB activities in lung and breast cancer cell lines.Quinoclamine affects the expression levels of genes involved in cell cycle or apoptosis.Quinoclamine down-regulates the expressions of UDP glucuronosyltransferase genes involved in phase II drug metabolism. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Kwon H ,et al. Induction of differentiation of U-937 cells by 2-chloro-3-amino-1,4-naphthoquinone. Res Commun Mol Pathol Pharmacol. 1997 Aug;97(2):215-27.[2]. Cheng WY, et al. Comprehensive evaluation of a novel nuclear factor-kappaB inhibitor, quinoclamine, by transcriptomic analysis. Br J Pharmacol. 2009 Jul;157(5):746-56.
溶解度数据
In Vitro: DMSO : 250 mg/mL (1204.18 mM; Need ultrasonic)配制储备液